Atlas Genetics, a British molecular diagnostics startup that creates rapid point-of-care tests for infectious diseases like chlamydia, will launch U.S. clinical trials with a $20 million Series C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback